论文部分内容阅读
目的:探讨高剂量左氧氟沙星治疗慢性阻塞性肺疾病急性加重期(AECOPD)下呼吸道细菌感染的临床疗效与安全性。方法:选择2009年5月-2011年2月我院收治的138例AECOPD下呼吸道细菌感染患者,并随机分为观察组和对照组各69例。对照组给予常规剂量200mg/100mL,2次/d;观察组给予400mg/100mL高剂量左氧氟沙星静脉滴注治疗,1次/d。比较两组治疗7～14d前、后情况。结果:对照组不良反应发生率为6.9%,治疗总有效率为86.9%;观察组不良反应发生率为6.2%,治疗总有效率为91.2%,比较两组上述两项指标没有显著性差异(P>0.05)。但是比较两组细菌清除率,观察组则明显优于对照组且两组差异性显著(P<0.05)。结论:对于老年慢性阻塞性肺疾病急性加重期下呼吸道细菌感染患者,应用高剂量左氧氟沙星治疗不良发应症状少,临床疗效确切,值得推广应用。
Objective: To investigate the clinical efficacy and safety of high-dose levofloxacin in the treatment of lower respiratory tract bacterial infections in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: A total of 138 AECOPD patients with lower respiratory tract infection admitted to our hospital from May 2009 to February 2011 were selected and randomly divided into observation group and control group with 69 cases each. The control group was given conventional dose of 200mg / 100mL, 2 times / d; the observation group was given 400mg / 100mL high-dose levofloxacin intravenously once a day. The two groups were compared before and after 7 ~ 14d. Results: The incidence of adverse reactions in the control group was 6.9%, the total effective rate was 86.9%. The incidence of adverse reactions in the observation group was 6.2% and the total effective rate was 91.2%. There was no significant difference between the two groups P> 0.05). However, comparing the bacterial clearance of the two groups, the observation group was significantly better than the control group and the difference was significant (P <0.05). Conclusions: For patients with lower respiratory tract bacterial infection in acute exacerbation of chronic obstructive pulmonary disease, the application of high-dose levofloxacin in the treatment of adverse symptoms is less and the clinical curative effect is exact, which is worthy of popularization and application.